Related Experiment Video

Updated: Apr 25, 2026

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

5.7K

Carfilzomib in multiple myeloma

Claudia Andreu-Vieyra1, James R Berenson

  • 1Oncotherapeutics , West Hollywood, CA , USA.

Expert Opinion on Biological Therapy
|August 30, 2014
PubMed
Abstract

Insights

Carfilzomib offers a promising new treatment for multiple myeloma (MM) patients who have relapsed or are refractory to other therapies. This proteasome inhibitor shows high response rates, even in patients resistant to bortezomib.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Multiple myeloma (MM) remains incurable despite advances, with patients often relapsing or becoming refractory to therapies.
  • There is a critical need for novel, effective, and well-tolerated treatments for relapsed/refractory MM.

Purpose of the Study:

  • To review preclinical and clinical data on carfilzomib for MM treatment.
  • To summarize carfilzomib's pharmacokinetics, pharmacodynamics, efficacy, safety, and tolerability.

Main Methods:

  • Review of preclinical and Phase I/II clinical trial data for carfilzomib.
  • Analysis of carfilzomib's distinct mechanism as a proteasome inhibitor compared to bortezomib.

Main Results:

  • Carfilzomib demonstrates high response rates as a single agent or in combination regimens for relapsed/refractory MM.
  • Effective in patients intolerant or resistant to bortezomib, including those with multiple prior therapies.
  • Encouraging response and survival rates observed in frontline settings with combination regimens.

Conclusions:

  • Carfilzomib is a significant advancement for managing relapsed/refractory MM.
  • Potential for carfilzomib in frontline MM treatment is substantial.
  • Ongoing Phase III trials and studies will further define carfilzomib's role in MM management.
Keywords:
carfilzomibepoxyketone classmultiple myelomaproteasome inhibitor

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Types of Intermediate Filaments01:31

Types of Intermediate Filaments

The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
3.7K
Fibril-associated Collagen01:11

Fibril-associated Collagen

Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
2.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867